Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03663218 · ClinicalTrials.gov registry record · NA

PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)

A NA study of Prostate Cancer, sponsored by Weill Medical College of Cornell University.

Active
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT03663218 is a NA study of Prostate Cancer that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 16 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03663218, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

Men with prostate cancer with Gleason Score of 8 or greater or clinical/radiographic evidence of T3 disease will be considered for this trial.

Conditions Studied

Interventions

  • RADIATION 5 Gy x 5 fractions
  • RADIATION 6 Gy x 5 fractions
  • RADIATION 6.5 Gy x 5 fractions
  • RADIATION maximum tolerated dose (6.5 Gy x 5 fractions)
  • RADIATION recommended phase 2 dose (6.5 Gy x 5 fractions)

Study Locations (1)

New York

  • Weill Cornell Medicine - New York

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2018-10-24
Est. Completion 2027-12-31
Phase NA

What the Registry Record Tells You About NCT03663218

The ClinicalTrials.gov registry entry for NCT03663218 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which 5 Gy x 5 fractions is the first listed.

NCT03663218 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03663218 about?

NCT03663218 is a clinical study titled "PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)". Men with prostate cancer with Gleason Score of 8 or greater or clinical/radiographic evidence of T3 disease will be considered for this trial.

What is the current status of trial NCT03663218?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2018-10-24. Estimated completion is 2027-12-31.

What conditions does trial NCT03663218 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03663218?

The interventions under investigation include: 5 Gy x 5 fractions (RADIATION), 6 Gy x 5 fractions (RADIATION), 6.5 Gy x 5 fractions (RADIATION), maximum tolerated dose (6.5 Gy x 5 fractions) (RADIATION), recommended phase 2 dose (6.5 Gy x 5 fractions) (RADIATION).

Who is sponsoring clinical trial NCT03663218?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03663218 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.